SCHEMBL11901653

SCHEMBL11901653

C[C@@H]1COc2c(F)ccc([N+](=O)[O-])c2N1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.35
ATM Q13315 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MAPT P10636 4/20 0.34
LMNA P02545 2/20 0.34
HTT P42858 2/20 0.34
ALDH1A1 P00352 5/20 0.34
HIF1A Q16665 1/20 0.34
TXNRD1 Q16881 1/20 0.33
TXNRD3 Q86VQ6 1/20 0.33
TXNRD2 Q9NNW7 1/20 0.33
VCAM1 P19320 1/20 0.33
AR P10275 1/20 0.32
TSHR P16473 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CHRNB4 P30926 2/20 0.32
CHRNA3 P32297 2/20 0.32
ACHE P22303 1/20 0.32
PGR P06401 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11902169 1.00 CASP6 (0.35) CASP6ATMTDP1MAPTLMNA
SCHEMBL11901655 1.00 CASP6 (0.35) CASP6ATMTDP1MAPTLMNA
SCHEMBL11902079 0.75 AR (0.33) ALDH1A1ARHSD17B10
SCHEMBL7389556 0.74 CHRNB4 (0.40) TDP1MAPTLMNAHTTALDH1A1
SCHEMBL9030228 0.74 CHRNB4 (0.40) TDP1MAPTLMNAHTTALDH1A1
SCHEMBL11901456 0.72 CASP6 (0.38) CASP6ATMTDP1MAPTLMNA
SCHEMBL9030621 0.72 PGR (0.35) ATMTDP1MAPTLMNAHTT
SCHEMBL9030626 0.72 PGR (0.35) ATMTDP1MAPTLMNAHTT
SCHEMBL11901972 0.70 CASP6 (0.36) CASP6ATMTDP1MAPTLMNA
SCHEMBL9031231 0.69 AKR1B1 (0.36) TDP1MAPTLMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
US-8653089-B2 Heterocyclic compounds and methods of use F. HOFFMANN-LA ROCHE AG (CH) 2014-02-18 US disclosed
EP-2673269-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2013-12-18 EP disclosed
WO-2012107465-A1 HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-08-16 WO disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2012-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202785-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE PIK3CA, PIK3CD, AKT3 CASP6 1777/4885ATM 1073/4885TDP1 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.